Abbott Laboratories 10-Q Summary: Period Ended September 30, 1997
Business Context and Reporting Period
This is an unaudited quarterly report (Form 10-Q) for Abbott Laboratories, an Illinois corporation, covering the three and nine months ended September 30, 1997. The company operates primarily in pharmaceutical, nutritional, hospital, and laboratory products. As of October 31, 1997, the company had approximately 765 million common shares outstanding.
Key Financial Metrics
| Metric | 3 Months Ended Sep 30, 1997 | 9 Months Ended Sep 30, 1997 |
|---|---|---|
| Net Sales | $2,865.2 million | $8,765.4 million |
| Net Earnings | $471.4 million | $1,527.8 million |
| Earnings Per Share | $0.61 | $1.98 |
| Gross Profit Margin | 56.7% | 56.8% |
| Operating Earnings | $621.5 million | $2,069.5 million |
| Cash Flow from Operations (9mo) | N/A | $2,010.2 million |
| Cash and Equivalents | $129.4 million | $129.4 million |
| Short-term Debt | $1,637.8 million | $1,637.8 million |
| Long-term Debt | $939.5 million | $939.5 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8.3% in the third quarter and 9.3% year-to-date compared to 1996, driven primarily by unit growth.
- Profitability: Net earnings rose 12.0% in the quarter and 11.4% year-to-date. Earnings per share increased 13.0% and 13.1%, respectively.
- Margins: Gross profit margin improved to 56.7% in the quarter (from 55.5% in 1996) due to productivity and cost improvements, partially offset by higher royalties and a stronger U.S. dollar.
- Expenses: Research and development expenses increased to $326.8 million (quarter) and $927.0 million (9 months), representing 11.4% and 10.6% of sales. Selling, general, and administrative expenses rose 9.7% and 11.0% respectively, net of favorable currency effects.
- Currency Impact: International sales were unfavorably affected by the stronger U.S. dollar by 7.9% in the quarter and 6.9% year-to-date.
Guidance, Outlook, Risks, and Unusual Items
Legal Proceedings: The company faces significant litigation risks, including:
- Antitrust Suits: Pending cases involve infant formula marketing (3 suits, 5 investigations) and prescription pharmaceutical pricing (146 suits, 2 investigations). A settlement of $1.5 million is pending for a Massachusetts infant formula case. The company denies all substantive allegations in pharmaceutical pricing suits.
- Patent Infringement: Abbott sued TorPharm regarding generic divalproex sodium (Depakote). In a separate case against Alra Laboratories, the court granted summary judgment in Abbott's favor, finding Alra's product infringes Abbott's patents.
- Environmental: The company is a potentially responsible party for cleanup costs at various locations but believes the ultimate disposition will not have a material adverse effect.
Acquisitions: In April 1997, Abbott acquired Sanofi's parenteral products business for approximately $200 million. In May 1996, it acquired MediSense for approximately $867 million.
Liquidity and Capital: The company maintains AAA (S&P) and Aa1 (Moody's) credit ratings. It has $1.5 billion in unused domestic lines of credit. During the first nine months of 1997, the company repurchased and retired 13.3 million shares for $820 million.
Legislative Risks: Ongoing government regulation and debate regarding healthcare payment and delivery could reduce prices or price increases for medical products.
Investor Verification Checklist
- Verify the status of the $1.5 million infant formula settlement in Massachusetts and the outcome of the Louisiana court denial.
- Monitor the progress of the multidistrict litigation (MDL 997) regarding prescription drug pricing, specifically the requirement for plaintiffs to prove wholesaler conspiracy.
- Confirm the integration and financial contribution of the Sanofi parenteral products acquisition.
- Review the impact of the stronger U.S. dollar on future international sales projections.
- Track the company's share repurchase program, noting the remaining authorization of 2.36 million shares.